Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06401824 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 1, 2024 to Apr 24, 2025
    • Site details revised at 3 of 3 sites
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will evaluate whether the combination of sacituzumab govitecan (SG) and bevacizumab will result in shrinkage of brain metastases from patients with non-squamous non-small cell lung cancer (NSCLC), with disease progression on chemotherapy and immunotherapy.
Trial Details
NCT Number NCT06401824
Lead Sponsor Maastricht University Medical Center
Collaborators: Gilead Sciences
Conditions
(from sponsor)		 NSCLC Stage IV, Brain Metastases, Adult
Related terms Brain Neoplasms, Carcinoma, Non-Small-Cell Lung
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov